CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 897 enrolled
Drug / intervention
Dabigatrandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04532528
NCT04532528N/ACompleted
CompareCT.gov

Relationship of Advanced Holding Education and ADherence on Antithrombotic in Younger SPAF Patients

Boehringer Ingelheim·observational·Posted Aug 31, 2020·Updated May 15, 2025

In Brief

An observational study evaluating Dabigatran for Atrial Fibrillation. Completed, enrolled 897 participants across 23 sites.

Detailed Summary

Lifelong oral anticoagulant (OAC) therapy is the preferred treatment for the prevention of thromboembolic events in the majority of patients with Atrial Fibrillation (AF). Adherence to medication is essential for valid treatment for OAC therapy. The study aims to explore whether the advanced educational intervention would improve the adherence to dabigatran.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesTaiwan
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedAug 31, 2020
Enrollment StartAug 27, 2020
Primary CompletionMay 8, 2023
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 5.8 years ago

Interventions

Dabigatrandrug

Dabigatran